Advertisement

Topics

RiboQuark Doses First Patient in China siRNA Trial

22:24 EST 14 Nov 2017 | ChinaBio Today

Kunshan RiboQuark Pharma has dosed the first person in a China trial of a siRNA ocular neuroprotectant therapy. The therapeutic (QPI-1007) treats a "stroke in the eye," known more technically as acute non-arteritic ischemic optic neuropathy (NAION). QPI-1007 temporarily inhibits expression of the apoptotic protein, Caspase 2. RiboQuark is a JV formed by two siRNA companies: Ribo Life Science, headquartered in Kunshan, Jiangsu Province, and Quark Pharma, a US-Israeli company. More details....

Share this with colleagues:

Original Article: RiboQuark Doses First Patient in China siRNA Trial

NEXT ARTICLE

More From BioPortfolio on "RiboQuark Doses First Patient in China siRNA Trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...